We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Portable Rapid Diagnostic Assay Identifies Hemorrhaging Patients Using Small Blood Sample

By LabMedica International staff writers
Posted on 29 Aug 2023

Hemorrhaging occurs when blood vessels are damaged due to a traumatic event, leading to either visible external or hidden internal bleeding. More...

While external bleeding is easily detectable, internal bleeding, also referred to as internal hemorrhaging, remains hidden from plain sight. Diagnosing internal bleeding demands clinical suspicion and subsequent assessment. Within hospital settings, advanced imaging can confirm these assessments, enabling timely surgical intervention to save lives. However, current methods for detecting hemorrhage are insufficient and require skilled operators, presenting significant diagnostic challenges. Now, a revolutionary internal hemorrhage diagnostic tool could change all that.

DioTeX Diagnostics (Baltimore, MD, USA), comprising a team of undergraduate biomedical engineers from Johns Hopkins University (Baltimore, MD, USA), is developing a portable, dependable, and accessible internal hemorrhage diagnostic tool. Their approach involves using a specific biomarker associated with hemorrhage to create a rapid immunochemistry-based test. By analyzing a small blood sample, this tool can swiftly identify patients with internal bleeding. This test has the potential to revolutionize internal hemorrhage diagnosis, as it can be conducted accurately and consistently by individuals with minimal training. This innovation holds the promise of faster and more appropriate hemorrhage care, potentially saving thousands of lives annually.

DioTeX has built a prototype of its portable rapid diagnostic assay designed to detect blood biomarkers linked to trauma-induced hemorrhage. This advancement aims to enhance the evaluation and management of internal trauma. Using the device, critical diagnostic results can be obtained and interpreted by anyone, regardless of location. To utilize the device, a blood sample is collected from behind the ear of a patient who may be experiencing internal bleeding. This process employs DioTeX's proprietary blood drawing mechanism. After approximately 5 minutes, users can interpret the test device's reading. A single line indicates no hemorrhage, while two lines indicate the presence of bleeding. The testing device requires minimal training, making it practical for use in settings with limited resources and in rural areas.

Related Links:
DioTeX Diagnostics 
Johns Hopkins University 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.